Fresh analysis indicates that individuals who come off popular GLP-1 drugs like Mounjaro or Wegovy tend to recover shed pounds much more quickly than those who stop traditional diet and exercise programs.
Research printed in a major medical journal points out that while overweight people often shed substantial amounts of their total mass while undergoing treatment, the weight returns at an estimated rate of nearly a kilo each month upon discontinuation.
"Individuals using such drugs should be cognizant of the danger of rapid weight regain when the treatment concludes," stated lead investigator Dr. Susan Jebb.
This pace of recovery suggests a return to original weight within about 18 months.
Comparing Approaches
The research, which examined dozens of trials involving over 9,000 of patients, contrasted the results of these new drugs with older methods.
Researchers note that people who lose weight through diet and exercise typically have a more gradual creep back—perhaps 0.1 kg a month—post-intervention.
Explaining the Fast Regain
Experts believe the way of the drugs explains the accelerated rebound.
GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Artificially providing GLP-1 concentrations far above than the body's typical production may cause the body to generate a reduced amount of its endogenous GLP-1, and could lessen responsiveness to its effects," noted Dr. Adam Collins, a dietetics expert.
"Withdrawal of this medication means appetite is no longer kept in check, making binge eating a significant risk."
An Ongoing Disease?
Health authorities advise the injections for people with obesity-related medical conditions, alongside prescribed lifestyle changes.
Many experts argue that, given the high risk of weight regain, the therapy should be considered ongoing.
This opinion is echoed by drug manufacturers, who note that the results "emphasize the chronic nature of obesity," comparing it to managing diseases like hypertension.
User Testimonies
People who have stopped the medication report a intense return of appetite.
"It felt as if something activating and you're instantly extremely hungry," said a patient.
The struggle is compounded if users have not developed lasting dietary or behavioural modifications during treatment.
Significant Use
Survey data show that a significant number of people in the UK have tried weight-loss jabs in the past year, with desire continuing to grow.
- Adoption is higher among women compared to men.
- The middle-aged demographic shows the highest level of interest.
- A large proportion access the medications through private healthcare rather than public health services.
Finally, experts stress that while the jabs are powerful tools for shedding pounds, they are not a magic fix and long-term success likely depends on integrated behavioural management.
